Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer

Summary

The primary objective of the study is to provide expanded access to and characterize the safety profile of tarlatamab in participants with advanced small cell lung cancer (SCLC) after two or more prior lines of treatment (including at least one platinum-based regimen). EA may still be available in countries outside of the United States.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications